成都先导药物开发股份有限公司（上海证券交易所股票代码：688222.SH，股票名称：成都先导）致力于打造全球一流的创新型生物医药企业，总部位于中国成都，在英国剑桥、美国休斯顿设有子公司。公司聚焦小分子及核酸新药的发现与优化，着力打造了DNA编码化合物库技术（包括DEL库的设计、合成和筛选及拓展应用）、基于分子片段和三维结构信息的药物设计技术（FBDD/SBDD）、寡聚核酸新药研发平台相关技术（STO）、靶向蛋白降解平台相关技术（TPD）等四个核心技术平台。通过新药研发服务、不同阶段在研项目转让以及远期的药物上市等多元化的商业模式，成都先导与全球数百家制药公司、生物技术公司、化学公司、基金会以及科研机构建立了合作。目前，公司有多个内部新药项目处于临床及临床前不同阶段。
HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.